- Summits
- Sponsorship
- Media Opportunities
- News
- About
MedTech Innovator (MTI), the world’s largest accelerator for medical technology startups, has announced its 2026 Accelerator Cohort alongside a significant new addition to its ecosystem: the MTI Index. Together, these developments signal a meaningful shift in how the global MedTech industry recognises, tracks, and engages with its most promising companies.
Selected from 1,835 global applicants, the 65 companies entering the 2026 programme represent the top 4% of submissions, a figure that speaks to how competitive the process has become. The cohort spans 18 US states and 16 countries, with international representation including the UK, Ireland, Switzerland, Italy, France, the Netherlands, Germany, Denmark, Spain, Israel, South Korea, Japan, New Zealand, and Canada.
The companies are distributed across six therapeutic areas: Cardiovascular & Interventional, Diagnostics & Monitoring, GI & Urology, Neurotech, Regenerative Medicine & Wound Care, and Surgical & Orthopedic, a spread that reflects both the breadth of unmet clinical need and the diversity of where MedTech innovation is happening today.
The full 2026 cohort comprises Approxima, Cannulight Technology, Chambertech, Flux Robotics, Galenband, HICKY, Lenneuro, Lucentia, Medyria, NEVENT, Noah Labs, OMINI, Prima Medical, SonoVascular, Spheric Bio, TAILRD Heart, Tau Medical, UltraSight, and Vektor Medical in Cardiovascular & Interventional; AcQumen Medical, AION Biosystems, BioSens8, Cymantic Medical, Dermagnostix, Eupnoos, Feminai, ImageAssist, OmniBuds, and WovenX Health in Diagnostics & Monitoring; BeCapio, Class Medical, Drive Medical, Imagine Devices, Optheras, Urologic Health, Vivifi Medical, and Wicked Technologies in GI & Urology; Axoft, BrainMatterZ, Cerevia Neurosciences, Envera Medical, Magnetic Tides, Panaxium Research, Panda Surgical, Quantanosis.ai, and Theta Neurotech in Neurotech; GenAssist, GenesisTissue, GeniPhys, Hy2Care, Lenoss Medical, OsteoCure Therapeutics, TissueForm, and Tissuelock in Regenerative Medicine & Wound Care; and Abanza, ForCast Orthopedics, OrthoPreserve, OrthoSens, Pathkeeper Surgical, Portal Instruments, Ring Rescue, Symphera, VIS, XEOS, and Zonova in Surgical & Orthopedic.
The four-month accelerator programme kicks off at the invitation-only Innovator Summit in San Francisco on 2–4 June, before moving toward its competitive finals at The MedTech Conference in Boston in October and the MedTech Strategist Innovation Summit in San Diego in November. Across these events, companies compete for a share of $800,000 in funding. Thirteen of the 65 will also participate in dedicated specialty tracks, run in collaboration with the American Heart Association and the American Society of Plastic Surgeons.
MTI’s track record gives context to why selection matters: since its founding, the programme has supported 838 graduates, brought over 500 products to market, maintained a 93% company survival rate over a decade, and helped generate $12 billion in follow-on funding across 63 acquisitions.
What sets this year’s announcement apart is the simultaneous launch of the MTI Index — a dynamic, time-banded recognition platform designed to make the MTI portfolio permanently discoverable and trackable by investors, health systems, and media.
Until now, cohort recognition was largely tied to a moment in time. The MTI Index changes that by turning each cohort into a living record, updated periodically to reflect commercial traction, growth milestones, and category-level trends. The 2026 cohort serves as its inaugural class, with specialty indexes by therapeutic category set to follow on a rolling basis.
For investors and strategics, the Index offers a structured way to identify and monitor vetted companies without relying on individual outreach or conference cycles. For the companies themselves, it represents sustained visibility with a qualified audience, something that typically requires significant time and resource to build independently.
For those tracking medtech innovation from a European vantage point, this cohort carries particular relevance. A notable share of the 2026 companies are headquartered in Europe or have clear European market ambitions, and the MTI Index makes it easier than ever to identify and engage with them on an ongoing basis.
It is also worth noting that this is not the first time MTI alumni have made their mark in a European context. At MedTech World Europe 2025 in Valletta last November, ten companies drawn from MTI cohorts spanning 2019 to 2025 presented their technologies to an international audience of investors and healthcare leaders at the Mediterranean Conference Centre. The ten — Luminoah, Innova Vascular, Otolith Labs, Entirety Biomedical, Plio Surgical, TYBR Health, Medasense Biometrics, Ankr Health, RenewRx, and CorNeat Vision — covered a broad range of clinical areas, from pain monitoring and women’s health to corneal restoration and addiction recovery. The quality and diversity of those presentations underscored just how strong the MTI pipeline is when it reaches European audiences.
The broader context for why this matters now is MedTech World Europe 2026, which is expanding significantly in scope and format. This November, MedTech World is introducing MedTech Malta Week, a five-day experience running from 9 to 13 November across both Malta and the island of Gozo.
The week opens with the inaugural Investors Retreat on Gozo (9–11 November), an exclusive gathering for accredited investors and senior industry leaders. Set against the Mediterranean, the Retreat is designed for the kind of deeper relationship-building that a conventional conference schedule rarely allows. Accepted accredited investors receive complimentary passes, and the programme includes a curated blend of networking, workshops with key opinion leaders, high-end hospitality, and cultural experiences including visits to the Citadella and winery experiences featuring Mediterranean cuisine.
On 11 November, the experience moves to Malta for a cultural immersion day through Valletta and Mdina — two of the island’s most iconic cities — before the main conference opens at the Mediterranean Conference Centre in Valletta on 12 and 13 November. Over those two days, the programme will feature keynotes, panel discussions, workshops, startup showcases, investor meetings, and the MedTech World Startup Pitch Competition.
The week closes with the MedTech World Gala Awards, recognising outstanding innovations, leaders, and organisations from across the global MedTech ecosystem.
With 65 newly recognised companies now entering the MTI Index and a European investor community increasingly attuned to where the best-vetted global innovations are emerging, MedTech Malta Week 2026 represents a timely convergence point for the sector.
Book your spot for MedTech Malta Week 2026.
